Existing oncology therapeutics are either so specific they can target only part of a tumor, or so generalized they kill healthy tissue. A new “Tumor Activated Therapy™” in development at the small ...
A novel tumor suppressor, BATF2, can be silenced by factors in the tumor microenvironment, leading to a reduced immune ...
How tumor microbes shape cancer: New insights into microbial diversity in the tumor microenvironment
Intratumoral microbiota—the microbial populations residing within solid tumors—have emerged as pivotal components of the tumor microenvironment (TME), influencing tumor initiation, progression, and ...
The gut microbiome has been shown to influence tumor growth and contribute to therapeutic resistance. Scientists have ...
“We are encouraged by the emerging data from our lung cancer programs, where systemically delivered Olvi-Vec continues to ...
In recent years, cancer immunotherapy has transformed the treatment landscape for a wide range of malignancies, offering ...
Researchers at the University of Massachusetts Amherst and the University of Massachusetts Chan Medical School have demonstrated in mice a new immunotherapy-based approach to pancreatic cancer ...
3don MSN
Immune sabotage: How a vitamin A byproduct compromises the body's normal anti-cancer response
Scientists at the Princeton University Branch of the Ludwig Institute for Cancer Research have identified novel mechanisms by ...
Immune checkpoint molecules play a crucial role in keeping the immune system in balance and preventing an attack on the ...
The Phase 1b/2 SCLC trial and Phase 2 VIRO-25 trial are actively enrolling in dose escalation cohorts with an aim to optimize efficacy, safety, and tolerability of Olvi-Vec. The trials are being ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback